Craft

OLYMVAX

Stock Price

¥10.8

2024-10-29

Market Capitalization

¥4.2 B

2024-10-29

Revenue

¥694.1 M

FY, 2025

OLYMVAX Summary

Company Summary

Overview
Chengdu Olymvax Biopharmaceuticals (成都欧林生物科技股份有限公司) is a biopharmaceutical company that produces and sells vaccines. It offers tetanus, haemophilus influenzae, meningococcal conjugate, and other vaccines.
Type
Public
Status
Active
Founded
2009
HQ
Chengdu, CN | view all locations
Website
http://en.olymvax.com/
Cybersecurity rating
Sectors

Key People

  • Fan Shaowen

    Fan Shaowen, General Manager, Chairman of the Board

    • Tan Yong, Chief Financial Officer

      • Ma Hengjun, Executive Vice General Manager

        • Wu Wei, Secretary of the Board

          LocationsView all

          3 locations detected

          • Chengdu, Si Chuan Sheng HQ

            China

            No. 99 Tianxin Road, Hi-Tech Zone (West)

          • Chengdu, Sichuan

            China

            No. 18, Section 2, Biocity Middle Road, Shuangliu District

          • Chongqing, Chongqing

            China

            No. 15, Building 2-1, Phase II, Qingfeng Hi-Tech Innovation Incubation Center Project

          OLYMVAX Financials

          Summary Financials

          Revenue (Q1, 2026)
          ¥155.2M
          Gross profit (Q1, 2026)
          ¥142.3M
          Net income (Q1, 2026)
          ¥27.2M
          Cash (Q1, 2026)
          ¥192.3M
          EBIT (Q1, 2026)
          ¥36.5M
          Enterprise value
          $4.5B

          Footer menu